12 月龄时接受 7 价肺炎球菌结合疫苗婴幼儿基础免疫系列接种减少剂量和 23 价肺炎球菌多糖疫苗后的调理吞噬活性。
Opsonophagocytic activity following a reduced dose 7-valent pneumococcal conjugate vaccine infant primary series and 23-valent pneumococcal polysaccharide vaccine at 12 months of age.
机构信息
Centre for International Child Health, Department of Paediatrics, University of Melbourne, Royal Children's Hospital, Melbourne, Australia.
出版信息
Vaccine. 2011 Jan 10;29(3):535-44. doi: 10.1016/j.vaccine.2010.10.046. Epub 2010 Oct 31.
Abstract
Opsonophagocytic activity (OPA) was measured following reduced infant doses of 7-valent pneumococcal conjugate vaccine (PCV-7) with or without 23-valent pneumococcal polysaccharide vaccine (PPV-23) at 12 months, and subsequent re-exposure to a small dose of pneumococcal polysaccharide antigens (mPPS) at 17 months. Fijian infants were randomized to receive 0, 1, 2, or 3 PCV-7 doses. Half received PPV-23 at 12 months and all received mPPS at 17 months. OPA was performed on up to 14 serotypes. Three and 2 PCV-7 doses resulted in similar OPA for most PCV-7 serotypes up to 9 months and for half of the serotypes at 12 months. A single dose improved OPA compared with the unvaccinated group. PPV-23 significantly improved OPA for all serotypes tested but in general, was associated with diminished responses following re-challenge.
摘要
调理吞噬活性（OPA）在婴儿接受 7 价肺炎球菌结合疫苗（PCV-7）低剂量接种，无论是否同时接种 23 价肺炎球菌多糖疫苗（PPV-23）后 12 个月，以及随后在 17 个月时再次接触小剂量肺炎球菌多糖抗原（mPPS）时进行测量。斐济婴儿被随机分为接受 0、1、2 或 3 剂 PCV-7。一半的婴儿在 12 个月时接种 PPV-23，所有婴儿在 17 个月时接种 mPPS。OPA 最多针对 14 种血清型进行。对于大多数 PCV-7 血清型，3 剂和 2 剂 PCV-7 接种在 9 个月时产生了相似的 OPA，在 12 个月时对一半的血清型产生了相似的 OPA。与未接种疫苗的组相比，1 剂疫苗可改善 OPA。PPV-23 显著提高了所有测试血清型的 OPA，但通常与再次挑战后的反应减弱有关。
相似文献
1
Opsonophagocytic activity following a reduced dose 7-valent pneumococcal conjugate vaccine infant primary series and 23-valent pneumococcal polysaccharide vaccine at 12 months of age.12 月龄时接受 7 价肺炎球菌结合疫苗婴幼儿基础免疫系列接种减少剂量和 23 价肺炎球菌多糖疫苗后的调理吞噬活性。
Vaccine. 2011 Jan 10;29(3):535-44. doi: 10.1016/j.vaccine.2010.10.046. Epub 2010 Oct 31.
2
Immunogenicity following the first and second doses of 7-valent pneumococcal conjugate vaccine in HIV-infected and -uninfected infants.免疫原性后第一和第二剂量的 7 价肺炎球菌结合疫苗在 HIV 感染和未感染的婴儿。
Vaccine. 2013 Jan 21;31(5):777-83. doi: 10.1016/j.vaccine.2012.11.076. Epub 2012 Dec 8.
3
Serotype-specific avidity is achieved following a single dose of the 7-valent pneumococcal conjugate vaccine, and is enhanced by 23-valent pneumococcal polysaccharide booster at 12 months.接种一剂 7 价肺炎球菌结合疫苗后可获得血清型特异性亲合力，并在 12 个月时通过 23 价肺炎球菌多糖疫苗加强剂增强。
Vaccine. 2011 Jun 15;29(27):4499-506. doi: 10.1016/j.vaccine.2011.04.038. Epub 2011 May 1.
4
Hyporesponsiveness to re-challenge dose following pneumococcal polysaccharide vaccine at 12 months of age, a randomized controlled trial.12 月龄时接种肺炎球菌多糖疫苗后再挑战剂量时反应低下：一项随机对照试验。
Vaccine. 2010 Apr 26;28(19):3341-9. doi: 10.1016/j.vaccine.2010.02.087. Epub 2010 Mar 4.
5
The 13-valent pneumococcal conjugate vaccine (PCV13) elicits cross-functional opsonophagocytic killing responses in humans to Streptococcus pneumoniae serotypes 6C and 7A.13 价肺炎球菌结合疫苗（PCV13）可诱导人体对肺炎链球菌血清型 6C 和 7A 产生交叉功能调理吞噬杀伤反应。
Vaccine. 2011 Sep 22;29(41):7207-11. doi: 10.1016/j.vaccine.2011.06.056. Epub 2011 Jul 18.
6
Decreased immune response to pneumococcal conjugate vaccine after 23-valent pneumococcal polysaccharide vaccine in children.儿童接种 23 价肺炎球菌多糖疫苗后对肺炎球菌结合疫苗的免疫应答降低。
Vaccine. 2014 Jan 9;32(3):417-24. doi: 10.1016/j.vaccine.2013.11.029. Epub 2013 Dec 2.
7
Immunogenicity and safety of 13-valent pneumococcal conjugate vaccine given to korean children receiving routine pediatric vaccines.13 价肺炎球菌结合疫苗在接种常规儿科疫苗的韩国儿童中的免疫原性和安全性。
Pediatr Infect Dis J. 2013 Mar;32(3):266-73. doi: 10.1097/INF.0b013e3182748bb6.
8
Pneumococcal conjugate vaccine-elicited antibody persistence and immunogenicity and safety of 13-valent pneumococcal conjugate vaccine in children previously vaccinated with 4 doses of either 7-valent or 13-valent pneumococcal conjugate vaccine.在先前已接种4剂7价或13价肺炎球菌结合疫苗的儿童中，13价肺炎球菌结合疫苗的肺炎球菌结合疫苗诱导的抗体持久性、免疫原性及安全性
Pediatr Infect Dis J. 2014 Oct;33(10):1065-76. doi: 10.1097/INF.0000000000000459.
9
Safety and immunogenicity of the 23-valent pneumococcal polysaccharide vaccine at 12 months of age, following one, two, or three doses of the 7-valent pneumococcal conjugate vaccine in infancy.12 月龄时，1 剂、2 剂或 3 剂婴幼儿期 7 价肺炎球菌结合疫苗后，23 价肺炎球菌多糖疫苗的安全性和免疫原性。
Vaccine. 2010 Apr 19;28(18):3086-94. doi: 10.1016/j.vaccine.2010.02.065. Epub 2010 Mar 1.
10
Safety and immunogenicity of a 13-valent pneumococcal conjugate vaccine compared to those of a 7-valent pneumococcal conjugate vaccine given as a three-dose series with routine vaccines in healthy infants and toddlers.与7价肺炎球菌结合疫苗相比，13价肺炎球菌结合疫苗在健康婴幼儿中与常规疫苗按三剂程序接种时的安全性和免疫原性。
Clin Vaccine Immunol. 2010 Jun;17(6):1017-26. doi: 10.1128/CVI.00062-10. Epub 2010 Apr 28.
引用本文的文献
1
Simplified 0+1 and 1+1 pneumococcal vaccine schedules in Ho Chi Minh City, Vietnam: protocol for a randomised controlled trial.越南胡志明市简化的 0+1 及 1+1 型肺炎球菌疫苗接种计划：一项随机对照试验方案。
BMJ Open. 2021 Nov 29;11(11):e056505. doi: 10.1136/bmjopen-2021-056505.
2
Immunogenicity and Immune Memory after a Pneumococcal Polysaccharide Vaccine Booster in a High-Risk Population Primed with 10-Valent or 13-Valent Pneumococcal Conjugate Vaccine: A Randomized Controlled Trial in Papua New Guinean Children.在接种过10价或13价肺炎球菌结合疫苗的高危人群中接种肺炎球菌多糖疫苗加强针后的免疫原性和免疫记忆：巴布亚新几内亚儿童的一项随机对照试验
Vaccines (Basel). 2019 Feb 4;7(1):17. doi: 10.3390/vaccines7010017.
3
Rationale and methods of a randomized controlled trial of immunogenicity, safety and impact on carriage of pneumococcal conjugate and polysaccharide vaccines in infants in Papua New Guinea.在巴布亚新几内亚开展的关于肺炎球菌结合疫苗和多糖疫苗对婴儿免疫原性、安全性及携带情况影响的随机对照试验的原理与方法
Pneumonia (Nathan). 2017 Dec 25;9:20. doi: 10.1186/s41479-017-0044-z. eCollection 2017.
4
Carrier priming to improve pneumococcal disease control and reduce the international program's cost in children.通过载体预激发改善肺炎球菌疾病控制并降低该国际项目在儿童中的成本。
Pneumonia (Nathan). 2016 Sep 27;8:16. doi: 10.1186/s41479-016-0016-8. eCollection 2016.
5
Potential carrier priming effect in Australian infants after 7-valent pneumococcal conjugate vaccine introduction.引入7价肺炎球菌结合疫苗后澳大利亚婴儿的潜在载体启动效应。
World J Clin Pediatr. 2016 Aug 8;5(3):311-8. doi: 10.5409/wjcp.v5.i3.311.
6
Pneumococcus with the "6E" cps Locus Produces Serotype 6B Capsular Polysaccharide.具有“6E” cps 基因座的肺炎球菌产生 6B 型荚膜多糖。
J Clin Microbiol. 2016 Apr;54(4):967-71. doi: 10.1128/JCM.03194-15. Epub 2016 Jan 27.
7
Characterization of 19A-like 19F pneumococcal isolates from Papua New Guinea and Fiji.来自巴布亚新几内亚和斐济的19A样19F肺炎球菌分离株的特征分析。
New Microbes New Infect. 2015 Jul 4;7:86-8. doi: 10.1016/j.nmni.2015.06.008. eCollection 2015 Sep.
8
Immunogenicity and safety of 23-valent pneumococcal polysaccharide vaccine as a booster dose in 12- to 18-month-old children primed with 3 doses of 7-valent pneumococcal conjugate vaccine.23价肺炎球菌多糖疫苗作为3剂7价肺炎球菌结合疫苗初免的12至18月龄儿童加强剂量的免疫原性和安全性
Hum Vaccin Immunother. 2014;10(7):1859-65. doi: 10.4161/hv.28642.
9
Pneumococcal polysaccharide abrogates conjugate-induced germinal center reaction and depletes antibody secreting cell pool, causing hyporesponsiveness.肺炎球菌多糖可消除结合疫苗诱导的生发中心反应和耗竭抗体分泌细胞池，导致低反应性。
PLoS One. 2013 Sep 12;8(9):e72588. doi: 10.1371/journal.pone.0072588. eCollection 2013.
10
New diagnostic criteria for common variable immune deficiency (CVID), which may assist with decisions to treat with intravenous or subcutaneous immunoglobulin.常见变异性免疫缺陷（CVID）的新诊断标准，这可能有助于决定使用静脉注射或皮下免疫球蛋白进行治疗。
Clin Exp Immunol. 2013 Nov;174(2):203-11. doi: 10.1111/cei.12178.
本文引用的文献
1
Immunogenicity of alternative regimens of the conjugated 7-valent pneumococcal vaccine: a randomized controlled trial.替代方案的 7 价结合型肺炎球菌疫苗的免疫原性：一项随机对照试验。
Pediatr Infect Dis J. 2010 Aug;29(8):756-62. doi: 10.1097/INF.0b013e3181d99345.
2
Hyporesponsiveness to re-challenge dose following pneumococcal polysaccharide vaccine at 12 months of age, a randomized controlled trial.12 月龄时接种肺炎球菌多糖疫苗后再挑战剂量时反应低下：一项随机对照试验。
Vaccine. 2010 Apr 26;28(19):3341-9. doi: 10.1016/j.vaccine.2010.02.087. Epub 2010 Mar 4.
3
Safety and immunogenicity of the 23-valent pneumococcal polysaccharide vaccine at 12 months of age, following one, two, or three doses of the 7-valent pneumococcal conjugate vaccine in infancy.12 月龄时，1 剂、2 剂或 3 剂婴幼儿期 7 价肺炎球菌结合疫苗后，23 价肺炎球菌多糖疫苗的安全性和免疫原性。
Vaccine. 2010 Apr 19;28(18):3086-94. doi: 10.1016/j.vaccine.2010.02.065. Epub 2010 Mar 1.
4
Increased risk of hospitalization for acute lower respiratory tract infection among Australian indigenous infants 5-23 months of age following pneumococcal vaccination: a cohort study.澳大利亚原住民婴儿 5-23 月龄在接种肺炎球菌疫苗后急性下呼吸道感染住院风险增加：一项队列研究。
Clin Infect Dis. 2010 Apr 1;50(7):970-8. doi: 10.1086/651079.
5
Do pneumococcal conjugate vaccines provide any cross-protection against serotype 19A?肺炎球菌结合疫苗对 19A 血清型是否提供任何交叉保护作用？
BMC Pediatr. 2010 Feb 2;10:4. doi: 10.1186/1471-2431-10-4.
6
Immunogenicity of a reduced schedule of pneumococcal conjugate vaccine in healthy infants and correlates of protection for serotype 6B in the United Kingdom.在英国，健康婴儿中肺炎球菌结合疫苗简化免疫程序的免疫原性和 6B 型血清型的保护相关性。
Pediatr Infect Dis J. 2010 May;29(5):401-5. doi: 10.1097/INF.0b013e3181c67f04.
7
Burden of disease caused by Streptococcus pneumoniae in children younger than 5 years: global estimates.5岁以下儿童肺炎链球菌所致疾病负担：全球估计数
Lancet. 2009 Sep 12;374(9693):893-902. doi: 10.1016/S0140-6736(09)61204-6.
8
Immunogenicity following one, two, or three doses of the 7-valent pneumococcal conjugate vaccine.一剂、两剂或三剂7价肺炎球菌结合疫苗后的免疫原性。
Vaccine. 2009 Sep 18;27(41):5685-91. doi: 10.1016/j.vaccine.2009.06.098. Epub 2009 Jul 17.
9
Identification of a simple chemical structure associated with protective human antibodies against multiple pneumococcal serogroups.鉴定与针对多种肺炎球菌血清型的保护性人类抗体相关的简单化学结构。
Infect Immun. 2009 Aug;77(8):3374-9. doi: 10.1128/IAI.00319-09. Epub 2009 May 18.
10
Immune response in infants to the heptavalent pneumococcal conjugate vaccine against vaccine-related serotypes 6A and 19A.婴儿对七价肺炎球菌结合疫苗针对疫苗相关血清型6A和19A的免疫反应。
Clin Vaccine Immunol. 2009 Mar;16(3):376-81. doi: 10.1128/CVI.00344-08. Epub 2009 Jan 14.
Zotero 插件